We are live on ! Find out more
Broadfin Capital

Broadfin Capital Portfolio holdings

AUM $747M Turnover 50.88%
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
+6.13%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$1.03B
AUM Growth
-$6.85M
Cap. Flow
+$37.9M
Cap. Flow %
3.69%
Top 10 Hldgs %
54.01%
Holding
84
New
13
Increased
14
Reduced
14
Closed
14
Avg Time Held Equity + Options
1.6 years
Top 10 Avg Time Held Equity + Options
1.1 years
Top 20 Avg Time Held Equity + Options
1 year
Avg Time Held Equity only
1.6 years
Top 10 Avg Time Held Equity only
1.2 years
Top 20 Avg Time Held Equity only
1 year

Sector Composition

Rank Sector Weight
1 Healthcare 83.13%
2 Miscellaneous 16.76%
3 Technology 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$732B
$115M 11.2%
+550,000
New +$114M
2016 Q2
0 quarters
HZNP
2
DELISTED
Horizon Therapeutics
HZNP
$113M 10.99%
6,863,848
+40,471
+0.6% +$655K
2013 Q3
11 quarters
NVDQ icon
3
DELISTED
Novadaq Technologies
NVDQ
$53.8M 5.23%
5,465,216
– –
2013 Q2
12 quarters
ANGO icon
4
AngioDynamics
ANGO
$455M
$51.8M 5.04%
3,607,282
+1,108,755
+44% +$13.9M
2013 Q2
12 quarters
TVTX icon
5
Travere Therapeutics
TVTX
$4.51B
$47.4M 4.61%
2,662,591
-297,199
-10% -$4.81M
2014 Q1
9 quarters
AVDL
6
DELISTED
Avadel Pharmaceuticals
AVDL
$47.2M 4.59%
4,394,464
– –
2013 Q2
12 quarters
PGNX
7
DELISTED
Progenics Pharmaceuticals
PGNX
$37.8M 3.67%
8,951,169
– –
2013 Q2
12 quarters
RPTP
8
DELISTED
Raptor Pharmaceutical
RPTP
$34.6M 3.37%
6,450,000
-550,000
-8% -$2.82M
2015 Q2
4 quarters
NVRO icon
9
DELISTED
Nevro
NVRO
$28.9M 2.81%
392,355
-275,552
-41% -$18.7M
2015 Q2
4 quarters
IOVA icon
10
Iovance Biotherapeutics
IOVA
$3.19B
$25.7M 2.5%
3,170,759
+1,065,240
+51% +$6.69M
2015 Q1
5 quarters
HRTX icon
11
Heron Therapeutics
HRTX
$48M
$22.6M 2.19%
1,250,104
-215,371
-15% -$4.2M
2014 Q1
9 quarters
CSII
12
DELISTED
Cardiovascular Systems
CSII
$22.6M 2.19%
1,227,501
-235,162
-16% -$3.67M
2016 Q1
1 quarter
PETX
13
DELISTED
Aratana Therapeutics
PETX
$21.7M 2.11%
3,428,865
– –
2014 Q1
9 quarters
LJPC
14
DELISTED
La Jolla Pharmaceutical
LJPC
$20.5M 1.99%
1,281,373
+116,000
+10% +$2.08M
2014 Q1
9 quarters
GNMX icon
15
DELISTED
Aevi Genomic Medicine Inc
GNMX
$18.7M 1.82%
3,370,306
+325,000
+11% +$1.71M
2014 Q4
6 quarters
TLGT
16
DELISTED
Teligent
TLGT
$18M 1.75%
251,650
+22,877
+10% +$1.33M
2013 Q4
10 quarters
SCTL
17
DELISTED
Societal CDMO
SCTL
$16.4M 1.59%
2,060,086
– –
2014 Q1
9 quarters
ENDP
18
DELISTED
Endo International
ENDP
$16M 1.56%
+1,028,802
New +$21.3M
2016 Q2
0 quarters
ATRS
19
DELISTED
Antares Pharma
ATRS
$15.6M 1.52%
14,885,393
-200,000
-1% -$193K
2013 Q4
10 quarters
ADXS
20
DELISTED
Advaxis Inc
ADXS
$13.7M 1.33%
112,701
– –
2015 Q1
5 quarters
ARLZ
21
DELISTED
Aralez Pharmaceuticals
ARLZ
$13.6M 1.32%
4,106,990
+306,990
+8% +$1.16M
2016 Q1
1 quarter
ELGX
22
DELISTED
Endologix
ELGX
$12.5M 1.21%
100,000
– –
2015 Q4
2 quarters
BDSI
23
DELISTED
BioDelivery Sciences International
BDSI
$12.2M 1.19%
5,188,794
– –
2013 Q2
12 quarters
RXDX
24
DELISTED
Ignyta
RXDX
$12.2M 1.19%
2,256,546
– –
2014 Q1
9 quarters
SPNE
25
DELISTED
SeaSpine Holdings
SPNE
$11.5M 1.12%
1,100,007
+100,000
+10% +$1.21M
2015 Q3
3 quarters

Similar funds

Broadfin Capital's Q2 2016 Portfolio in Review

As of Q2 2016, Broadfin Capital held 84 positions worth $1.03B, down 0.66% from $1.04B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Broadfin Capital deployed $37.9M of net new capital in Q2 2016, opening 13 new positions and adding to 14 existing holdings. Its largest new stake was Endo International: 1,028,802 shares worth $16M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 78% a quarter earlier, followed by Miscellaneous and Technology.

On the sell side, the largest reduction was Nevro, an estimated $18.7M trimmed.

  • Broadfin Capital's largest Q2 2016 buy was Endo International: 1,028,802 shares worth $16M.
  • Broadfin Capital added most to AngioDynamics in Q2 2016, an estimated $13.9M increase.
  • Broadfin Capital's biggest Q2 2016 reduction was Nevro, cutting an estimated $18.7M.
  • Broadfin Capital fully exited XenoPort in Q2 2016, selling an estimated $7.18M.
  • Broadfin Capital's ten largest holdings make up 54% of its $1.03B portfolio in Q2 2016.
  • Broadfin Capital opened 13 new positions and closed 14 in Q2 2016.
  • Broadfin Capital's portfolio value fell 0.66% quarter-over-quarter to $1.03B.

Based on Broadfin Capital's 13F filing for Q2 2016, filed 15 Aug 2016.